Acceleron Pharma (XLRN) Misses Q1 EPS by 12c

Acceleron Pharma (NASDAQ: XLRN) reported Q1 EPS of ($0.66), $0.12 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $3.91 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M